The lifeblood of collaborative research at UAB is an Institutional Center infrastructure that embodies comfortable coexistence among strong Departments and Center organizations. Over the past few years, interdisciplinary approaches to CF science have blossomed at our institution from a focus on cellular, molecular and translational aspects of the disease. Very recently, with a concerted emphasis on translational science, UAB has positioned itself as an emerging leader in CF patient oriented research. The richness of CF cellular biology at UAB has grown in parallel with this clinical and translational expansion. A P30 CF Core Center in Birmingham will propel investigators at UAB and collaborating sites towards improved understanding of the most basic underpinnings of cystic fibrosis pathogenesis, and the ways this information can be aggressively applied to experimental therapeutics. This UAB P30 includes three Scientific Cores to help organize efforts of CF faculty towards this common and essential goal. These include: Core A: Cell Model and Assay Core (KL Kirk, PI);Core B: Mouse Models Core (DM Bedwell, PI);and Core C: Clinical Core (JP Clancy, PI). Each Core will provide leading edge assays, specialized reagents and sound experimental expertise. The Center has also recruited new investigators through a Pilot and Feasibility mechanism integral to Center prosperity. In addition to providing a platform from which new junior and senior scientists can be brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Three Pilot and Feasibility Projects are proposed: Project 1: SM Rowe, PI. Role of Flavonoids in CFTR Biogenesis and Activation;Project 2: G Liu, PI. Mechanisms and Therapeutic Implications of HMGB1 in CF Lung Inflammation;Project 3: L Gerald, PI. The Relationship Between Health Literacy, Treatment Adherence, and Outcomes in CF. The UAB CF and Translation Core Center will consolidate and accelerate a large number of CF research programs locally and nationally. Progress will be measured by important new contributions and scientific discovery designed to improve the lives of patients with CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK072482-05
Application #
8074967
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (J1))
Program Officer
Mckeon, Catherine T
Project Start
2007-05-01
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
5
Fiscal Year
2011
Total Cost
$861,058
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Keating, Dominic; Marigowda, Gautham; Burr, Lucy et al. (2018) VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379:1612-1620
Tipirneni, Kiranya E; Zhang, Shaoyan; Cho, Do-Yeon et al. (2018) Submucosal gland mucus strand velocity is decreased in chronic rhinosinusitis. Int Forum Allergy Rhinol 8:509-512
Serocki, Marcin; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis 21:183-202
Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3:
Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583
Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8
Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :
Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102
McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304

Showing the most recent 10 out of 175 publications